HC Wainwright Reaffirms Buy Rating for Pharming Group (NASDAQ:PHAR)

HC Wainwright reiterated their buy rating on shares of Pharming Group (NASDAQ:PHAR) in a research report report published on Thursday, Benzinga reports. The brokerage currently has a $37.00 price target on the stock.

Pharming Group Stock Up 4.8 %

Pharming Group stock opened at $8.70 on Thursday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 2.65 and a current ratio of 3.39. The business’s 50-day simple moving average is $8.05 and its two-hundred day simple moving average is $8.53. The company has a market cap of $585.89 million, a PE ratio of -54.38 and a beta of 0.15. Pharming Group has a fifty-two week low of $6.65 and a fifty-two week high of $13.20.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, August 1st. The company reported ($0.01) EPS for the quarter. Pharming Group had a negative return on equity of 5.69% and a negative net margin of 4.65%. The company had revenue of $74.09 million during the quarter, compared to analysts’ expectations of $71.95 million. During the same quarter in the previous year, the company earned $0.02 EPS. Equities analysts anticipate that Pharming Group will post -0.15 EPS for the current year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC increased its holdings in Pharming Group (NASDAQ:PHAR) by 75.4% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 41,110 shares of the company’s stock after purchasing an additional 17,675 shares during the quarter. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 at the end of the most recent reporting period. 0.03% of the stock is owned by institutional investors and hedge funds.

Pharming Group Company Profile

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.